COMMUNIQUÉS West-GlobeNewswire

OSE Immunotherapeutics and the FoRT Foundation Announce Completion of Enrollment in Combi-TED, a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Nivolumab or Docetaxel in Patients with Non-Small Cell Cancer
11/09/2025
OSE Immunotherapeutics and the FoRT Foundation Announce Completion of Enrollment in Combi-TED, a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Nivolumab or Docetaxel in Patients with Non-Small Cell [...]
EssilorLuxottica: Nombre total de droits de vote et d’actions composant le capital social au 31 août 2025
11/09/2025
Nombre total de droits de vote et d’actions composant le capital social au 31 août 2025 (Conformément à l’article L.233-8 II du Code de Commerce et aux articles 221-1 et 223-16 du Règlement Général de l’AMF) Paris, [...]
EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of August 31, 2025
11/09/2025
Disclosure of Share Capital and Voting Rights Outstanding as of August 31, 2025 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des [...]
Guidance for the 2025/26 financial year
11/09/2025
ANNOUNCEMENT NO. 291 11 September 2025 Guidance for the 2025/26 financial year ChemoMetec today approved the annual report for 2024/25, including the guidance for 2025/26, which is considered inside information. For [...]
Annual Report 2024/25 - Growing revenue and EBITDA
11/09/2025
ANNOUNCEMENT NO. 292 11 September 2025 Annual Report 2024/25 (1 July 2024 - 30 June 2025) Growing revenue and EBITDA ChemoMetec’s revenue grew by 22% to DKK 495.6 million in 2024/25, and operating profit (EBITDA) [...]
Aesthetic Room Opens New Aesthetic Medicine Center in South Tyrol (Alto Adige) Near Merano and Bolzano
11/09/2025
Algund/Lagundo, South Tyrol (Alto Adige), Italy , Sept. 11, 2025 (GLOBE NEWSWIRE) -- Aesthetic Room , a new center for modern, minimally invasive aesthetic medicine , has officially opened in Algund , near Merano and [...]
Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225
11/09/2025
Supports Clinical Development of CLR 121225, Actinium-Labeled Compound for the Treatment of Solid Tumors FLORHAM PARK, N.J. and GARCHING, Germany and MUNICH, Germany, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Cellectar [...]
FibroBiologics Announces Positive IND-Enabling Updates Demonstrating Potential of Fibroblast Spheroids in Chronic-Relapse Psoriasis Treatment
11/09/2025
Pilot studies underway to advance IND-enabling preclinical development HOUSTON, Sept. 11, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270 [...]
Safety Shot Launches BONK Holdings to Build Treasury in $2.5 Billion BONK Ecosystem
11/09/2025
Company Forms New Subsidiary to House Digital Asset Strategy; Executes $5 Million Purchase to Increase BONK Treasury to Over $63 Million SCOTTSDALE, AZ, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT [...]
SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $23.6 Million in Gross Proceeds
11/09/2025
NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for [...]
Intercept Announces Voluntary Withdrawal of OCALIVA® for Primary Biliary Cholangitis (PBC) from the US Market; US Clinical Trials Involving Obeticholic Acid Placed on Clinical Hold
11/09/2025
MORRISTOWN, N.J., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a wholly owned biopharmaceutical subsidiary of Alfasigma S.p.A., today announced its decision to voluntarily withdraw OCALIVA ® ( [...]
Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings
11/09/2025
Presentations collectively highlight pilavapadin’s potential to improve pain management care for patients with diabetic peripheral neuropathic pain (DPNP) Breadth of the data across Phase 2 program to be discussed at [...]
Profusa Adopts NVIDIA-Powered Technology to Build AI-Driven Insight Portal for Continuous Biomarker Monitoring
11/09/2025
Company expects early 2026 rollout in EEA; physician portal combines Lumee™ oxygen monitoring with NVIDIA NeMo to deliver AI-driven clinical workflows BERKELEY, Calif, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“ [...]
RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Fall Investment Conference 2025 on September 16th
11/09/2025
MOUNTAIN VIEW, Calif., Sept. 11, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a life sciences company developing innovative targeted oncology therapies and commercializing [...]
GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
11/09/2025
No decline in lung function observed at 6-week interim analysis builds upon positive safety and biomarker data Phase 2a study fully enrolled; Topline data on track for Q3 2025 Currently available treatments for IPF are [...]
Anteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders
11/09/2025
MINNEAPOLIS and BRISBANE, Australia, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ( Anteris or the Company ) (NASDAQ: AVR , ASX: AVR), a global structural heart company committed to designing, [...]
Nacuity Pharmaceuticals Announces Positive Data from Clinical Trial Evaluating NPI-001 to Treat Retinitis Pigmentosa Associated with Usher Syndrome
11/09/2025
NPI-001 shows more than 50% reduction in photoreceptor loss caused by RP associated with USH over two years NPI-001 was well tolerated, with no persistent drug-related adverse events Results were leveraged to design [...]
Athira Pharma Announces Reverse Stock Split
11/09/2025
BOTHELL, Wash., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (“Athira” or “Company”) (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health [...]
Femasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed®
11/09/2025
-- Following the Setup Kit, the Insemination Kit completes the sperm preparation portion of FemSperm enabling gynecology call point activation to drive revenue growth -- ATLANTA, Sept. 11, 2025 (GLOBE NEWSWIRE) -- [...]

Pages